Join to view full profile
500 University DrHershey, PA 17033
Phone+1 800-243-1455
Dr. Kirschbaum is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
SUNY Downstate Health Sciences UniversityInternship, Internal Medicine, 1986 - 1987
State University of New York Downstate Medical Center College of MedicineClass of 1986
Certifications & Licensure
NY State Medical License 1988 - 2026
PA State Medical License 2012 - 2016
NV State Medical License Active through 2013
CA State Medical License 2002 - 2012
American Board of Internal Medicine Internal Medicine
Clinical Trials
- Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia
- Aflibercept in Treating Patients With Myelodysplastic Syndromes
Publications & Presentations
PubMed
- 3 citationsA phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium StudyMark Kirschbaum, Paul Frankel, Timothy W. Synold, Jasmine Zain, David F. Claxton
British Journal of Haematology. 2018-02-01 - 8 citationsA phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium studyMark Kirschbaum, Paul Frankel, Timothy W. Synold, Zhiliang Xie, Yun Yen
Leukemia & Lymphoma. 2016-02-19 - 290 citationsResults of the phase i trial of RG7112, a small-molecule MDM2 antagonist in leukemiaMichael Andreeff, Kevin R. Kelly, Karen W.L. Yee, Sarit Assouline, Roger Strair
Clinical Cancer Research. 2016-02-15
Press Mentions
Cyclacel Reports Preliminary Data from Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients with Solid Tumors and Lymphoma at ENA 2022October 26th, 2022- Cyclacel Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business UpdateAugust 10th, 2022
- BioSpace Movers & Shakers, Oct. 30October 29th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: